首页> 外文期刊>Clinical and vaccine immunology: CVI >Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.
【24h】

Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.

机译:新生儿恒河猕猴对麻疹病毒DNA疫苗的免疫反应不良,表达血凝素和融合糖蛋白。

获取原文
获取原文并翻译 | 示例
           

摘要

A vaccine that would protect young infants against measles could facilitate elimination efforts and decrease morbidity and mortality in developing countries. However, immaturity of the immune system is an important obstacle to the development of such a vaccine. In this study, DNA vaccines expressing the measles virus (MeV) hemagglutinin (H) protein or H and fusion (F) proteins, previously shown to protect juvenile macaques, were used to immunize groups of 4 newborn rhesus macaques. Monkeys were inoculated intradermally with 200 μg of each DNA at birth and at 10 months of age. As controls, 2 newborn macaques were similarly vaccinated with DNA encoding the influenza virus H5, and 4 received one dose of the current live attenuated MeV vaccine (LAV) intramuscularly. All monkeys were monitored for development of MeV-specific neutralizing and binding IgG antibody and cytotoxic T lymphocyte (CTL) responses. These responses were poor compared to the responses induced by LAV. At 18 months of age, all monkeys were challenged intratracheally with a wild-type strain of MeV. Monkeys that received the DNA vaccine encoding H and F, but not H alone, were primed for an MeV-specific CD8(+) CTL response but not for production of antibody. LAV-vaccinated monkeys were protected from rash and viremia, while DNA-vaccinated monkeys developed rashes, similar to control monkeys, but had 10-fold lower levels of viremia. We conclude that vaccination of infant macaques with DNA encoding MeV H and F provided only partial protection from MeV infection.
机译:一种可以保护年轻婴儿免受麻疹的疫苗可以促进消除努力,并降低发展中国家的发病率和死亡率。但是,免疫系统的不成熟是这种疫苗开发的重要障碍。在这项研究中,表达麻疹病毒(MEV)血凝蛋白(H)蛋白或H的DNA疫苗和融合蛋白(F)蛋白(以前显示的保护幼猕猴)用于免疫4新生恒河猕猴的组。猴子在出生时和10个月大时用200μg的每种DNA接种猴子。作为对照组,类似地,用编码流感病毒H5的DNA接种了2个新生猕猴,其中4猕猴接受了一剂当前的活体衰减MEV疫苗(LAV)。监测所有猴子以开发MEV特异性中和IgG抗体以及细胞毒性T淋巴细胞(CTL)反应的发展。与LAV引起的响应相比,这些反应很差。在18个月大时,所有猴子都被野生型MEV菌株受到了气管内的挑战。收到编码H和F的DNA疫苗(但不是单独H)的猴子是针对MEV特异性CD8(+)CTL反应的,而不是用于抗体的产生。 lav疫苗接种的猴子受到皮疹和病毒血症的保护,而DNA接种式猴子会出现皮疹,类似于对照猴子,但病毒血症的水平低10倍。我们得出的结论是,用编码MEV H和F的DNA接种猕猴,仅提供了MEV感染的部分保护。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号